PL359327A1 - Kompozycje zawierające blokery transferu L-Dopa zkomórek nerkowych do leczenia choroby Parkinsona - Google Patents

Kompozycje zawierające blokery transferu L-Dopa zkomórek nerkowych do leczenia choroby Parkinsona

Info

Publication number
PL359327A1
PL359327A1 PL01359327A PL35932701A PL359327A1 PL 359327 A1 PL359327 A1 PL 359327A1 PL 01359327 A PL01359327 A PL 01359327A PL 35932701 A PL35932701 A PL 35932701A PL 359327 A1 PL359327 A1 PL 359327A1
Authority
PL
Poland
Prior art keywords
dopa
renal cell
parkinson
treatment
disease
Prior art date
Application number
PL01359327A
Other languages
English (en)
Inventor
Patricio Soares-Da-Silva
Original Assignee
Portela & Companhia S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portela & Companhia S.A. filed Critical Portela & Companhia S.A.
Publication of PL359327A1 publication Critical patent/PL359327A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL01359327A 2000-03-14 2001-03-13 Kompozycje zawierające blokery transferu L-Dopa zkomórek nerkowych do leczenia choroby Parkinsona PL359327A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0006063A GB2348371B (en) 2000-03-14 2000-03-14 Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
PCT/EP2001/002896 WO2001068065A2 (en) 2000-03-14 2001-03-13 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
PL359327A1 true PL359327A1 (pl) 2004-08-23

Family

ID=9887552

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01359327A PL359327A1 (pl) 2000-03-14 2001-03-13 Kompozycje zawierające blokery transferu L-Dopa zkomórek nerkowych do leczenia choroby Parkinsona

Country Status (23)

Country Link
US (1) US20040242503A1 (pl)
EP (1) EP1267853B1 (pl)
JP (1) JP3677002B2 (pl)
KR (1) KR100738746B1 (pl)
CN (1) CN1262269C (pl)
AR (1) AR035567A1 (pl)
AT (1) ATE275397T1 (pl)
AU (1) AU781280B2 (pl)
BR (1) BR0109220A (pl)
CA (1) CA2402712C (pl)
CZ (1) CZ297123B6 (pl)
DE (1) DE60105401T2 (pl)
DK (1) DK1267853T3 (pl)
ES (1) ES2228858T3 (pl)
GB (1) GB2348371B (pl)
HU (1) HUP0300130A3 (pl)
MX (1) MXPA02009043A (pl)
PL (1) PL359327A1 (pl)
PT (1) PT1267853E (pl)
RU (1) RU2266111C2 (pl)
SI (1) SI1267853T1 (pl)
TR (1) TR200402661T4 (pl)
WO (1) WO2001068065A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US7381772B2 (en) * 2003-12-12 2008-06-03 E. I. Du Pont De Nemours And Company Toughened poly(lactic acid) compositions
AU2005252220B2 (en) 2004-06-04 2011-06-02 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
WO2006004552A1 (en) * 2004-07-07 2006-01-12 Kampavata Ab Transgenic non-human animal for use in research models for studying parkinson's disease
CN101137639B (zh) * 2005-03-11 2012-05-23 霍华德弗洛里生理医学实验研究所 类黄酮化合物及其用途
GB0505756D0 (en) * 2005-03-21 2005-04-27 Mars Uk Ltd Method
US20090012170A1 (en) * 2005-09-21 2009-01-08 Helena Nissinen Treatment of symptoms of motor dysfunction
EP1957109A2 (en) * 2005-12-02 2008-08-20 Sirtris Pharmaceuticals, Inc. Modulators of cdc2-like kinases (clks) and methods of use thereof
DK1959948T3 (da) 2005-12-05 2012-08-20 Xenoport Inc Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf
TW200843731A (en) 2006-12-21 2008-11-16 Xenoport Inc Catechol protected levodopa diester prodrugs, compositions, and methods of use
EP2125702A1 (en) 2006-12-21 2009-12-02 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
AU2008257437A1 (en) * 2007-02-14 2008-12-04 Mars, Incorporated Neurogenic compounds
BRPI0801239A2 (pt) * 2008-04-01 2009-11-17 Ache Lab Farmaceuticos Sa uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
US9290445B2 (en) 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
CN105902535A (zh) * 2009-04-13 2016-08-31 中国医学科学院药物研究所 黄芩素在制备预防和治疗帕金森病药物中的应用
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CN101797243B (zh) * 2010-03-23 2012-01-18 广东药学院 一种含有左旋多巴和冰片的组合物及其应用
KR101327936B1 (ko) * 2011-07-06 2013-11-13 한국식품연구원 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물
CN102755312A (zh) * 2012-07-16 2012-10-31 中国科学院大连化学物理研究所 具有黄酮骨架结构的化合物作为帕金森症治疗药物的应用
GB201302755D0 (en) 2013-02-15 2013-04-03 Mars Inc Horse supplement
CN103211832A (zh) * 2013-04-24 2013-07-24 无锡艾德美特生物科技有限公司 含杨酶苷或/和杨梅素的药物组合物及其在制备帕金森治疗药物中的用途
CN104116730A (zh) * 2013-04-26 2014-10-29 中国科学院大连化学物理研究所 二氢杨梅素作为活性成份在制备帕金森症治疗药物中的应用
KR101583399B1 (ko) * 2013-10-22 2016-01-08 충북대학교 산학협력단 아사리닌 또는 (-)-세사민을 함유하는 파킨슨병 예방 또는 치료용 약학조성물
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
KR20180034030A (ko) * 2016-09-27 2018-04-04 (주)아모레퍼시픽 소장 상피세포에서의 카테킨 흡수 증진제
CN111329853A (zh) * 2020-04-21 2020-06-26 遵义医科大学 一种治疗帕金森病的药物组合物及其应用和治疗帕金森病的药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) * 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
JPS6450877A (en) * 1987-08-20 1989-02-27 Ichimaru Pharcos Inc Oxygen radical catching and removing agent
JPH035423A (ja) * 1989-06-01 1991-01-11 Ichimaru Pharcos Co Ltd フラボノイド含有過酸化脂質生成抑制剤
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
JPH09241637A (ja) * 1996-03-14 1997-09-16 Chugai Pharmaceut Co Ltd 活性酸素ラジカル除去用組成物およびその方法
GB9702310D0 (en) * 1997-02-05 1997-03-26 Univ Hertfordshire Invention
CA2306875C (en) * 1997-10-24 2011-01-04 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
JPH11323326A (ja) * 1998-02-06 1999-11-26 Nagaoka Koryo Kk 活性酸素消去剤、皮膚保全剤および変色防止剤
FR2787319B1 (fr) * 1998-12-22 2002-06-14 Oreal Utilisation d'hydroxystilbenes pour la teinture, composition prete a l'emploi les contenant et procede de teinture
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
AU2003207734C1 (en) * 2002-01-28 2009-10-08 Kyowa Kirin Co., Ltd. Methods of treating patients suffering from movement disorders

Also Published As

Publication number Publication date
AU781280B2 (en) 2005-05-12
HUP0300130A2 (en) 2003-05-28
TR200402661T4 (tr) 2004-11-22
DE60105401D1 (de) 2004-10-14
GB0006063D0 (en) 2000-05-03
DK1267853T3 (da) 2005-01-10
JP2003526658A (ja) 2003-09-09
ES2228858T3 (es) 2005-04-16
JP3677002B2 (ja) 2005-07-27
GB2348371B (en) 2001-04-04
KR20030095184A (ko) 2003-12-18
CA2402712A1 (en) 2001-09-20
MXPA02009043A (es) 2004-08-19
HUP0300130A3 (en) 2005-11-28
CN1429109A (zh) 2003-07-09
CA2402712C (en) 2005-05-17
AU5828301A (en) 2001-09-24
EP1267853A2 (en) 2003-01-02
RU2266111C2 (ru) 2005-12-20
US20040242503A1 (en) 2004-12-02
AR035567A1 (es) 2004-06-16
CZ297123B6 (cs) 2006-09-13
CN1262269C (zh) 2006-07-05
ATE275397T1 (de) 2004-09-15
WO2001068065A9 (en) 2002-07-18
BR0109220A (pt) 2003-03-18
PT1267853E (pt) 2004-12-31
DE60105401T2 (de) 2005-10-13
WO2001068065A3 (en) 2002-02-21
SI1267853T1 (en) 2005-04-30
GB2348371A (en) 2000-10-04
EP1267853B1 (en) 2004-09-08
CZ20023348A3 (cs) 2003-02-12
KR100738746B1 (ko) 2007-07-12
WO2001068065A2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
GB2348371B (en) Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
DK0841904T3 (da) Orale farmaceutiske præparater med forsinket frigivelse af reversible protonpumpeinhibitorer
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
WO2006037061A3 (en) Compositions and methods of using d-dopa to treat parkinson's disease
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
EP1602645A4 (en) NITROGENIC HETEROCYCLIC DERIVATIVE WITH 2,6-DISUBSTITUTED STYRYL REST
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
WO2000001415A3 (en) Use of inhibitors of protein kinase c epsilon to treat pain
WO2004012722A3 (en) Bicifadine formulation
NZ523606A (en) Pharmaceutical compositions and methods for use
PT1441708E (pt) Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo
WO2005020954A3 (en) Proton pump inhibitor formulations, and methods of preparing and using such formulations
EP1550443A4 (en) COMPOSITION AGAINST STRESS-BASED DISEASES
WO2001054707A3 (de) Veränderung von oberflächenproteomem durch aminopeptidase-inhibitoren
WO2002053097A3 (en) Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
WO2001034174A3 (en) Methods for administration of therapeutic agents on an antiangiogenic schedule
DK1330428T3 (da) Faste præparater til oral administration indeholdende ikke-hygroskopiske salte af L-carnitin og alkanoyl-L-carnitiner med taurinchlorid
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
DK1062954T3 (da) Anvendelse af itakonsyre til regulering af det glykotiske stofskifte
ATE301469T1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
WO2002068389A3 (de) Indolderivate mit inhibitorischer wirkung auf phenoloxidasen
AU2001292499A1 (en) 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10- tetrahydropyridazino(4,5-b)quinoline-1,10-dione and the use thereof for the treatment of pain

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)